QbD in Test Method Development & Validation
Created by: Ronald D. Snee, PhD, Snee Associates, LLC Snee-QbDTestMethodDevelopment-Pharm-ProcessingFeb2014Download
To access this post, you must purchase MEMBER PLUS + or MEMBER PLUS 6M FREE.
Created by: Ronald D. Snee, PhD, Snee Associates, LLC Snee-QbDTestMethodDevelopment-Pharm-ProcessingFeb2014Download
Created by: Chris Latoz & Kim Huynh-ba Combination products are therapeutic and diagnostic products that include two or more of the following: drug, biologic, and device. These products are needed for enhanced clinical outcomes and have more than one Mode of Action (MOA). Therefore, they require a more complex regulatory pathway and compliance with a […]
Created by: Kimberly Wallbank & Nicole Damour Product complaints and reports of adverse events are unwelcome events at any company, especially if a product recall must be considered. However, these must be handled promptly and with all due diligence to prevent authentic drug- related events from negatively impacting the health and well-being of patients. This […]
Created by: Chris Gray, Principal Consultant, CAI Your company has received an FDA warning letter, now what? As an organization finds itself in uncharted waters due to inspection results, the leader’s job is to chart a course and speed to re-inspection success without everyone jumping ship. Leaders must remember historical averages for change success hovers […]
Created by: Harry Benson, Director, Human Performance, CAI This paper intends to provide guidance on talent planning, with specific emphasis on role clarity. Given the flurry of activity being conducted during capital projects and transitions to operations, developing a talent plan may appear to be somewhat administrative or insufficiently urgent. This often leads site leaders […]
31 E Kings Highway
2nd Floor Haddonfield, NJ 08033